Eugia US

What Eugia US does

Eugia US LLC is a specialty pharmaceutical company headquartered in East Windsor, New Jersey, and a wholly-owned subsidiary of Aurobindo Pharma Ltd. (BSE/NSE: AUROBINDO), one of India's largest generic manufacturers. Operating under the Eugia Pharma Specialities Limited umbrella following an August 2022 rebranding from AuroMedics Pharma LLC, Eugia US develops, manufactures, and distributes FDA-approved generic injectable pharmaceuticals to US healthcare institutions, including acute care hospitals, health systems, GPOs, independent hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics. Its therapeutic portfolio spans antibiotics, antivirals, respiratory agents, hematology, cardiovascular, central nervous system, and oncology treatments, with an explicit product strategy aimed at in-demand and short-supply categories. The group has accumulated 184 ANDA approvals across its manufacturing facilities, with its portfolio extending into ready-to-use formulations such as Cyclophosphamide and higher-value oncology adjacencies including Pomalidomide Capsules (US market estimated at $3.3 billion) and Everolimus Tablets (184th ANDA, $78 million market, Q1 FY27 launch).

Distribution is hybrid: direct ordering via phone, fax, and email — with same-day shipping for orders placed before 12:00 PM EST — plus wholesale routing through AmerisourceBergen, Cardinal, McKesson, and M&D. Products are invoiced at published Wholesale Acquisition Cost with a $500 minimum order, and the commercial organization layers Territory Business Managers across defined US geographies (Ohio Valley, Florida, Texas/Oklahoma, Mid-Atlantic) with Strategic Account Managers handling national IDNs and GPO relationships. The company maintains a 59-acre, fully automated distribution center in East Windsor, NJ.

The business model is a one-time unit-pricing sale of generic injectable SKUs into institutional channels, with economics tied to volume share within hospital formularies and GPO contracts. In May 2024 Eugia US divested a manufacturing facility to Empower Pharma for $52 million as part of an asset-restructuring move, while continuing to grow its commercial product portfolio. Recent product launches (Pomalidomide, Everolimus, Bendamustine, Cyclophosphamide, Plerixafor) and ongoing TBM and sales-leadership hiring point to a deliberate mix shift toward higher-value specialty and oncology generics. There is no disclosed use of artificial intelligence or machine learning in the company's operations, R&D, or commercial functions.

Name

Eugia US

Legal name

Eugia US LLC

Website

https://eugiaus.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

101–250 employees

Short description

Eugia US LLC is a specialty pharmaceutical subsidiary of Aurobindo Pharma that develops, manufactures, and distributes FDA-approved generic injectable pharmaceuticals to US hospitals, health systems, GPOs, and wholesalers, with 184 ANDA approvals and an oncology-expanding product pipeline.

Ownership category

akta.pro rank

Product category

Generic Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Generic injectables
• Sterile pharmaceuticals
• Hospital drug supply
• FDA-approved generics
• Injectable manufacturing

Headquarters

HQ city

Windsor

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Generic Injectable Pharmaceutical Sales: Eugia US generates revenue through the manufacture and sale of FDA-approved generic injectable pharmaceuticals. Products are sold to healthcare institutions including hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics through direct sales and wholesale distribution.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Eugia US develops, manufactures, markets, and distributes FDA-approved generic injectable pharmaceuticals across therapeutic classes including antibiotics, antivirals, respiratory, hematology, cardiovascular, central nervous system, and oncology treatments. Products are sold to acute care hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics through direct sales and wholesale distribution channels.

Product overview

Eugia US (a subsidiary of Aurobindo Pharma, formerly AuroMedics Pharma LLC) is a specialty pharmaceutical company focused on manufacturing and marketing generic injectable medications. The company offers an extensive portfolio targeting in-demand, short-supply products across therapeutic categories including antibiotics, antivirals, respiratory agents, hematology, cardiovascular drugs, central nervous system medications, and oncology treatments. Products serve institutional settings including acute care hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics. The portfolio includes injectables like Icatibant Injection, Carboprost Tromethamine, Vancomycin, Amphotericin B Liposome, Cyclophosphamide, and numerous other generic sterile injectables. Eugia operates with a focus on high-quality products, competitive pricing, and consistent supply.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Injectables Portfolio

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Empower PharmaminorOthers · 1 May 2024In May 2024, US-based Empower Pharma acquired manufacturing assets from Eugia US LLC, a subsidiary of Aurobindo Pharma Ltd., for $52 million. The acquisition was intended to strengthen Empower's capacity in sterile medication production for maternal health therapeutics. The deal involved Eugia's manufacturing facility in New Jersey.

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Viatris (formerly Mylan): Large diversified generic manufacturer with a sterile injectables franchise that overlaps Eugia US's portfolio; notably acquired and transferred products to Eugia historically, and competes for the same institutional customers.
• Baxter International: Major supplier of injectable and infusion pharmaceuticals to US hospitals, with overlapping presence in anesthesia, critical care, and oncology injectables served by Eugia US.
• Teva Pharmaceutical Industries: Global generic powerhouse with a broad sterile injectables portfolio in the US; competes with Eugia US across multiple therapeutic classes, particularly through GPO and hospital channels.
• Sandoz (Novartis): Global generic pharmaceuticals leader with a large sterile injectables business serving US hospitals; competes broadly with Eugia US across most therapeutic categories but at significantly greater scale and breadth.
• Pfizer (Hospira): Through the Hospira acquisition, Pfizer operates one of the largest US injectable pharmaceutical businesses, directly competing with Eugia US in oncology, anti-infectives, and other sterile injectable categories.

Direct peers

• Fresenius Kabi: One of the largest US suppliers of generic injectable pharmaceuticals, with a comparable sterile injectables portfolio across hospitals, GPOs and IDNs — directly competing with Eugia US across antibiotics, analgesics, and oncology injectables.
• Hikma Pharmaceuticals: Major US generic injectable manufacturer with overlapping hospital-channel focus and a comparable portfolio of sterile injectables, including short-supply and specialty products targeted at the same institutional customers as Eugia US.
• Apotex: Canadian-headquartered generic pharmaceutical company with a US injectables presence, overlapping portfolio of sterile injectables and competing for the same institutional and GPO contracts.
• Amphastar Pharmaceuticals: US-focused specialty injectable pharmaceutical company with a similar hospital-channel strategy and overlapping injectable portfolio, including products addressing shortage-prone therapeutic categories.

Emerging players

• Gland Pharma: India-based sterile injectables manufacturer with growing US presence (now part of Fosun), competing in similar injectable therapeutic categories and leveraging comparable cost advantages to Aurobindo/Eugia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eugiaus

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eugia US